ANAPTYSBIO, INC
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $234.6M | $91.3M | $17.2M | $10.3M | $63.2M |
| Research and development | $136.0M | $163.8M | $132.3M | $88.8M | $98.5M |
| Operating expenses | $186.7M | $206.2M | $181.6M | $125.4M | $120.0M |
| Operating income | $47.9M | -$114.9M | -$164.4M | -$115.2M | -$56.8M |
| Interest expense | — | — | — | — | $0 |
| Pretax income | -$13.1M | -$145.2M | -$163.6M | -$128.7M | -$57.8M |
| Income tax expense | $164,000 | $3,000 | -$4,000 | $24,000 | $0 |
| Net income | -$13.2M | -$145.2M | -$163.6M | -$128.7M | -$57.8M |
| Balance Sheet | |||||
| Cash and equivalents | $238.2M | $123.1M | $36.0M | $71.3M | $495.7M |
| Current assets | $350.2M | $431.9M | $406.8M | $447.2M | $553.9M |
| Total assets | $364.4M | $483.8M | $452.4M | $610.4M | $643.1M |
| Current liabilities | $38.6M | $45.4M | $37.4M | $26.1M | $16.1M |
| Stockholders' equity | $37.2M | $70.9M | $88.1M | $262.1M | $356.4M |
| Cash Flow Statement | |||||
| Cash from operations | $19.7M | -$135.3M | -$120.8M | -$73.6M | -$45.9M |
| Depreciation and amortization | $559,000 | $606,000 | $652,000 | $675,000 | $619,000 |
| Stock-based compensation | $36.1M | $34.0M | $33.2M | $27.4M | $15.3M |
| Capital expenditure | $87,000 | $358,000 | $807,000 | $358,000 | $1.4M |
| Free cash flow | $19.6M | -$135.7M | -$121.6M | -$74.0M | -$47.3M |
| Share repurchases | $68.6M | $456,000 | $50.0M | $0 | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 29.1M · Free float 17.5%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.